Crossmark

Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study

Crossref DOI link: https://doi.org/10.1007/s00262-024-03899-9

Published Online: 2025-01-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Yanxin

Luo, Yuxi

Liu, Yunwei

Luo, Daya

Liu, Anwen
Funding

Funding for this research was provided by:

Graduate Innovation Program of Nanchang University (YC2023- B092, YC2023- B092)

National Natural Science Foundation of China (82260628 and 82060577)

Natural Science Foundation of Jiangxi Province (20232ACB206042)

Wu Jieping Medical Foundation (320.6750.2024-16-10)
License Information

Text and Data Mining valid from 2025-01-03

Version of Record valid from 2025-01-03
More Information

Article History

Received: 18 June 2024

Accepted: 16 November 2024

First Online: 3 January 2025

Declarations

:

: The authors declare no competing interests.

: Animal experimentation care is in accordance with the institution's guidelines.

Document is current

Any future updates will be listed below